Jonathan D M Atkinson,Rachel S Moodie
Jonathan D M Atkinson
This article examines strategies used by innovators in the pharmaceutical industry in order to extend the legal monopolies available to them in order to prevent generic sales of their products for as long as possible. We examine patent proc...
Phoebe Heseltine
Phoebe Heseltine
Different rules, different results: patent litigation after In re Baxter [0.03%]
不同的规则，不同的结果：In re Baxter判决后的专利诉讼
Bryan J Vogel,Sharon E Roberg-Perez
Bryan J Vogel
Better protection for patentees: preliminary injunctions in the EU for pharmaceutical patent matters [0.03%]
改进专利权保护：欧盟药品专利诉讼的临时禁令措施
Andreas von Falck,Miriam Gundt
Andreas von Falck
Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂ [0.03%]
针对炎症的创新策略减少前列腺素E2的产生及作用路径
Jessica K Norberg,Earlphia Sells,Hui-Hua Chang et al.
Jessica K Norberg et al.
The PGE2 pathway is important in inflammation-driven diseases and specific targeting of the inducible mPGES-1 is warranted due to the cardiovascular problems associated with the long-term use of COX-2 inhibitors. This review focuses on pate...
Hisanori Yagami,Hiroshi Kato,Kanta Tsumoto et al.
Hisanori Yagami et al.
Based on the size and scope of the present global market for medicine, monoclonal antibodies (mAbs) have a very promising future, with applications for cancers through autoimmune ailments to infectious disease. Since mAbs recognize only the...
The patent situation concerning the treatment of diseases associated with autoantibodies directed against G-protein-coupled receptors [0.03%]
与针对G蛋白偶联受体的自身抗体相关疾病治疗的专利情况
Annekathrin Haberland,Gerd Wallukat,Ingolf Schimke
Annekathrin Haberland
Agonist-like autoantibodies against receptors of the G-protein-coupled signal cascade have been identified as the pathogenic principle for a variety of diseases, especially those of the heart and vascular system. Consequently, the eliminati...
Olga Khorkova,Jane Hsiao,Claes Wahlestedt
Olga Khorkova
Over the recent decade oligonucleotides have become an important new class of molecules, allowing therapeutic intervention through targets previously thought 'undruggable'. One of the new avenues opened up by oligonucleotide-based drugs was...
Learning from practice: compulsory licensing cases and access to medicines [0.03%]
从实践中学习：强制许可案例与药品可及性
Beatrice Stirner,Harry Thangaraj
Beatrice Stirner
Compulsory license is one of the safeguards that international IP law provides to address the undesired effects of pharmaceutical patents on access to important medicines. This article looks into three important case examples to analyze the...
The ITC as an attractive patent litigation forum for the biotechnology and pharmaceutical industry [0.03%]
美国国际贸易委员会：生物技术和制药行业的专利诉讼优选场所
Carlyn A Burton,Lisa E Margonis
Carlyn A Burton